250,000 euros subsidy for UT spin-off MyLife Technologies
MyLife Technologies BV, a spin-off company of UT research institute MESA+, received a subsidy of 250,000 euros of the ministries of Education, Culture and Science and Economic Affairs, in the form of a loan. The subsidy is intended for converting scientific innovative knowledge into commercial applications. The company develops sticking plasters that have hundreds of tiny needles in them, with which you can painlessly administer vaccines in a completely new fashion.
State secretary Sander Dekker announced that eight start-up companies will receive a loan of 250,000 from the government, from the funds of the science financing programme Take-off. This programme is intended to help companies market their innovative knowledge. According to Dekker, scientific knowledge gains incredible surplus value - both socially and economically - if you manage to convert it into applications that are beneficial to society. "The eight start-ups that today are granted a loan from us are textbook examples of this."
The company MyLife Technologies BV started in 2012, springs from UT research institute MESA+ and is established at the Innovation Campus Kennispark in Enschede. The company develops sticking plasters that have hundreds of tiny needles made of ceramic material in them. The needles, which have a cross-section of only several millionths of a millimetre and which penetrate into the superficially located immune cells in the skin, are so small that the patient won't even feel them.
The technology of MyLife Technologies therefore also offers opportunities for the administration of other categories of medication through the skin. In addition to the development of vaccine plasters the company will work on applications for other medication at the same time.
MyLife Technologies will use the subsidy to show that the product is ready for clinical trials. According to Dr Regina Luttge, who developed the technology and who also helped found MyLife Technologies, the subsidy is an important step for the continued development of the product. "It's about a completely new application method. In order to make clinical application possible, it's important that we can show that our method works great on the basis of scientific data. This requires funds."
The loans are a part of the science financing programme Take-off. The Dutch Technology Foundation STW, ZonMW and the Netherlands Organisation for Scientific Research (NWO) assessed the proposals that were sent in. For their assessment they held scientific innovation, commercial perspective and quality of the teams and their connection to the University as the most important criteria.